Overview
Bradley B. Pua, M.D. is Chief of the Division of Interventional Radiology and Director of the Lung Screening Program at New York Presbyterian Weill Cornell Medicine.
Dr. Pua obtained a B.S. degree in Chemistry from New York University (NYU) and continued at NYU School of Medicine where he was awarded his M.D. degree. He completed three years of surgical residency at New York University Medical Center prior to deciding to pursue a career in Interventional Radiology and subsequently completed a fellowship in Interventional Radiology at NewYork-Presbyterian Hospital-Weill Cornell Campus & Memorial Sloan Kettering Cancer Center. Dr. Pua remained at Cornell to complete his diagnostic radiology residency and was elected to serve as Chief Resident in his final year.
Dr. Pua's clinical expertise is in Interventional Radiology and performs a variety of interventional procedures including, but not limited to: arterial embolizations, stent placements, tumor ablations, biopsies and vascular access. His interests include both pediatric interventions and minimally invasive cancer therapy, with a particular focus on thoracic tumors.
Dr. Pua's research interests are in simulators for medical education as well as thoracic tumor treatments for which he has written both review articles and book chapters.
Dr. Pua is a reviewer for the Radiology, Journal of Vascular and Interventional Radiology, Clinical Imaging and Journal of Translational Lung Cancer Research.
Top Procedures:
1. Embolization and ablation of various tumors.
2. Pediatric Interventions
3. Management of Vascular Malformations
4. Image Guided Biopsy
Highlights
- 1Journal of the American College of Radiology : JACR · 2023
- 2Journal of the American College of Radiology : JACR · 2023
- 3
Publications
Funding
Active
2 grants- Co-IUM1CA186712-07The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials NetworkNational Cancer Institute · 2021–2027 · via The Ohio State University· 2 renewals
- Co-IFEAST-ORG-002Federated Ecosystem for Analytics and Standardization Technologies. FEASTARPA-H · 2024–2026 · via DNA Hive, LLC
Completed grants (4)
- PIRU 224881-01Service Agreement for Study: GVI-1028 HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal CentersRockefeller University · 2022–2023Contract
- MPIR01CA207442-01CASTL: Cessation and Screening to Save LivesNational Cancer Institute · 2018–2023 · via Sloan-Kettering Institute for Cancer Research
- Co-IJ&J Biopharma 213315-02Molecular and cellular profiling of preinvasive and minimally invasive lesions to understand the biology underlying progression from indolent to more invasive tumorsJohnson & Johnson · 2020–2022
- KPU01HL088476-05Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed ThrombolysisNational Heart, Lung, and Blood Institute · 2011–2016 · via Washington University, The
Clinical research
Active
1 study- PINCT07046832Clinical Evaluation of an Intra-procedural 3D Needle Guidance Platform for Soft Tissue Tumors or Organs Requiring Percutaneous Biopsy as an Adjunct to Standard Image GuidanceNA · MediView XR · OPEN TO ACCRUAL (as of 2025)Oncology; Interventional Radiology; Liver Carcinoma; Renal Carcinoma; Biopsy
Completed & closed trials (5)
- PINCT03315910Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening SitesPHASE4 · Memorial Sloan Kettering Cancer Center · IRB STUDY CLOSURE (as of 2026)Smoking Cessation
- PIA Pilot Study to Evaluate Mobile Low-dose Computed Tomography Lung Cancer Screening Implementation in an Urban Setting.Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2025)
- PIUse of Virtual Reality/Augmented Reality device for students and practitioners in an Interventional Radiology settingWeill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2025)
- PINCT05890872A Clinical Study of Aliya™ Pulsed Electric Fields (PEF) Delivered Prior to Standard of Care Treatment for Advanced CancerNA · Galvanize Therapeutics, Inc. · CLOSED TO ACCRUAL (as of 2024)Lung Neoplasm Malignant
- PINCT03315910Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening SitesPHASE4 · Memorial Sloan Kettering Cancer Center · IRB STUDY CLOSURE (as of 2021)Smoking Cessation
News mentions
- New Mobile Lung Cancer Screening Unit Launches to Improve Access to Care for New YorkersOctober 15, 2025
A state-of-the-art health screening van launched this month is bringing advanced imaging technology and health education directly to New Yorkers who are at the greatest risk of developing lung cancer.
Mentoring
- NGNaveen GallaMD mentee · Class of 2018
- SJSeong Jun JangMD mentee · Class of 2023
- JKJulie KimMD mentee · Class of 2022
External relationships
Advisory/Scientific Board Member
DNA Hive, LLC · Galvanize Therapeutics, Inc. · GE Healthcare · MediView XR
Proprietary Interest
Oxford University Press Inc.
Other
Galvanize Therapeutics, Inc. · GE Healthcare · MediView XR